SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and rising volume have drawn attention, with traders linking the move to Starknets privacy and Bitcoin-DeFi initiatives and its post-quantum security narrative. Sentiment is broadly bullish on momentum and the projects technology, though some traders question whether gains can hold amid token-unlock and dilution concerns.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injectives proposed supply-squeeze update, which traders say could double INJs deflation rate if approved, is fueling bullish discussion alongside progress in tokenization and institutional finance. Optimists point to burns, staking and ecosystem growth, while skeptics remain wary of the tokens prolonged decline and question whether those developments will translate into sustained demand.

Bitdeer Technologies Group engages in the cryptocurrency mining industry. It generates income through its proprietary mining datacenters. The firm handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The company was founded by Wu Jihan in December 2021 and is headquartered in Singapore.

Bitdeer Technologies Group. - Ordinary Shares - Class A

Bitdeer Technologies Holding Co

Bitdeers AI/HPC expansion is drawing attention, particularly its announced long-term Norway data-center lease, while the companys at-the-market share offering has fueled concerns about dilution amid weak price action. Bulls point to the AI infrastructure opportunity alongside Bitcoin mining, while skeptics question whether the growth will translate into shareholder gains.

Alignment Healthcare, Inc. is a holding company, which offers a consumer-centric platform that delivers customized health care solutions to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. It offers health plan options through Alignment Health Plan, and partners with select health plans to help deliver better benefits at lower costs. The company was founded by John E. Kao in 2013 and is headquartered in Orange, CA.

Alignment Healthcare Inc

Alignment Healthcares largest California Medicare Advantage contract fell from four to 3.5 stars, putting its eligibility for quality bonus payments at risk and driving a sharp selloff. Traders debate how much this could weigh on future earnings, with some expecting the company to challenge the rating and others viewing the potential 2028 impact as substantial.

Wachovia Corporation, a financial holding company, provides commercial and retail banking services, and other financial services. Wachovia was a diversified financial services company based in Charlotte, North Carolina. Before its acquisition by Wells Fargo in 2008, Wachovia was the fourth-largest bank holding company in the United States based on total assets. Wachovia provided a broad range of banking, asset management, wealth management, and corporate and investment banking products and services. At its height, it was one of the largest providers of financial services in the United States, operating financial centers in 21 states and Washington, D.C., with locations from Connecticut to Florida and west to California.

Wells Fargo & Co.

Wells Fargo is drawing attention ahead of its Q3 earnings as bank shares face pressure from rising Treasury yields and concerns about margins and deposit costs. Traders are split between buying the pullbackciting Wells Fargos Morgan Stanley upgrade and improving prospects after the asset-cap removaland waiting for earnings to clarify the outlook.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT traders are weighing a rebound against lingering concerns from the Wanchain bridge exploit and ongoing airdrop/unlock-related selling. Bulls point to the mainnet rollout, validator and partnership developments, and reported Coinbase availability as signs of adoption, while skeptics remain cautious about supply pressure and the exploits impact on confidence.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMP is drawing attention for a technical rebound, with traders watching a break above resistance near $26$27 and citing bullish chart patterns. Many are optimistic about its capped token supply and planned V4 and institutional-market expansion, while others remain frustrated by uneven price action; the breakout thesis is speculative.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is drawing attention amid a sharp pullback across uranium and nuclear stocks, with traders divided over whether the shares are forming a bottom or facing further pressure as enthusiasm for the nuclear theme cools. Cigar Lakes temporary production suspension added supply concerns, though Cameco said operations resumed and its production outlook was unchanged; bulls continue to cite long-term nuclear demand and Westinghouse exposure.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

Hyperliquids buyback-and-burn program, funded by protocol revenue, is a major focus as traders react to HYPEs rally and fresh highs. Bulls see recurring buybacks and growing platform activity as supportive, while others point to token unlocks, profit-taking, and pullback risk.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

Bitcoins rebound and traders view that it may have bottomed are fueling bullish interest in MSTX, a 2x leveraged MSTR ETF. Some traders remain cautious about its volatility and leverage decay, with bearish options activity viewed by some as hedging rather than a directional bet.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +9.88% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Lipocine Appoints Michael J. Grissinger to Board of Directors

Lipocine Appoints Michael J. Grissinger to Board of Directors Lipocine Appoints Michael J. Grissinger to Board of Directors PR Newswire SALT LAKE CITY, Aug. 3, 2026 SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary...

Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know

Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial

Equity

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.


Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.read more...

New Strong Sell Stocks for January 19th

APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.

 New Strong Sell Stocks for Jan. 14

APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

Marc Duey Acquires 21,459 Shares of Aprea Therapeutics (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey purchased 21,459 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were acquired at an...

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications.

Aprea Therapeutics Inc

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.6044
Prev Close	$0.5582
Open	$0.5571
Dividend Yield	0.00%
50-Day Moving Average	$0.7276
Beta	0.73
Avg. Volume	194,935.25
PE Ratio	-0.56

52-Week High	$1.69
52-Week Low	$0.548
Market Capitalization	$7.61M
EPS (Annual)	-$1.93
Price to Book	0.19
Revenue Per Employee	$35,719.88

Feed

News

Sentiment

Fundamentals

Info

APRE Fundamentals